九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO

证券之星07-06

证券之星消息，九洲药业(603456)07月06日在投资者关系平台上答复投资者关心的问题。

投资者提问：请问公司与艾力斯在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？

九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！

本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2649647913?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-06 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649647913","market":"fut","top_or_hot":-1,"title":"九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/603456\">九洲药业</a>(603456)07月06日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：请问公司与<a href=\"https://laohu8.com/S/688578\">艾力斯</a>在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？</p><p>九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！</p><p>本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 16:54 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026070600022695.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，九洲药业(603456)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司与艾力斯在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026070600022695.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688578","symbol_name":"艾力斯","start_time":0,"source_url":"https://stock.stockstar.com/RB2026070600022695.shtml","article_id":"2649647913","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649647913","pubTimestamp":1783328066,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，九洲药业(603456)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司与艾力斯在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603456":"九洲药业","688578":"艾力斯","BK0070":"员工持股","BK0239":"医药制造"},"translate_title":"Jiuzhou Pharmaceutical: At present, the company's services for Ellis are mainly focused on API CDMO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603456":1.5,"688578":1.5},"content_text":"证券之星消息，九洲药业(603456)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司与艾力斯在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649647913","isCrawlerRequest":true}